Kornimate/medical-research-clean huggingface dataset:
perineural catheter insertion distance for continuous peripheral nerve blocks

Conditions: Lower Extremity Surgery; Upper Extremity Surgery; Post-operative Pain

Summary: this is a research study to determine if the effects of continuous peripheral nerve blocks are influenced by the distance of insertion past the needle tip of the perineural catheter.

specific aim: research study to determine the relationships between perineural catheter insertion distance and subsequent continuous peripheral nerve block effects. hypothesis: during ultrasound-guided perineural catheter placement, inserting the catheter 0-1cm past the needle tip is associated with decreased postoperative pain compared with inserting the catheter 5-6cm past the needle tip.

Eligibility criteria:
inclusion criteria: * undergoing surgery with a planned popliteal perineural catheter for postoperative analgesia * age 18 years or older exclusion criteria: * pregnancy * inability to communicate with the investigators and hospital staff * incarceration * clinical neuropathy in the surgical extremity * chronic high-dose opioid use * history of opioid abuse

Keywords: pain surgery catheter nerve block popliteal sciatic femoral interscalene ucsd moderate-to-severe pain perineural catheter orthopedic surgery
nutrition intervention in aids wasting

Conditions: HIV Wasting Syndrome

Summary: there are no guidelines for appropriate nutritional management of weight loss or wasting in hiv infection. some treatments may increase weight, but without improving muscle mass or quality of life. in this clinical trial aids patients with wasting are randomized to one of three nutritional strategies and studied over a 12-week period: 1) optimal oral nutrition with counseling and protein and calorie supplementation, and a placebo pill; 2) optimal oral nutrition with the oral androgen, oxandrolone at 20 mg daily; and 3) optimal oral nutrition with progressive resistance training (prt). in all participants, dietary intervention is maximized by weekly personalized counseling to address individual issues and concerns. two primary outcomes are assessed: thigh muscle mass and quality of life. our findings can be used to develop guidelines for standards of nutritional care among aids patient with the wasting syndrome.


Eligibility criteria:
inclusion criteria: * loss of 10% of usual body weight, or loss of 5% of usual body weight within the previous 6 months, or bmi20kg/m2. if the candidate is taking a protease inhibitor, he/she must have not regained weight since initiating the medication over a period of at least 4 weeks prior to screening. * documented hiv-positive * able to eat * english-speaking * compliance with medical regimens * for heterosexually active women: willingness to use an effective means of birth control * patient and physician not planning to start new treatments for hiv infection or weight loss during the 12 weeks of study. exclusion criteria: * vomiting 1 time/day or diarrhea 4 times/day on average in the previous week * fever 101 f within the previous week * receiving induction treatment for one of the following (new diagnosis or recurrence within 4 weeks): pneumocystis carinii pneumonia cryptococcal meningitis cytomegalovirus retinitis or pneumonitis toxoplasmosis mycobacterium avium complex visceral kaposi's sarcoma lymphoma pulmonary tuberculosis * received corticosteroids, estrogens, progesterones, androgens, oral anticoagulants, or growth hormone within the previous three months * history of life-threatening reaction to oxandrolone or testosterone * currently pregnant * history of congestive heart failure, myocardial infarction, angina/coronary artery disease, uncontrolled hypertension, cerebrovascular accident, hepatic failure, bleeding disorder, diabetes, nephrotic syndrome, cancer of the breast or prostate, or hypercalcemia * milk product allergy * current use of injected drugs * participation in an exercise program or strength training within the previous 4 weeks * any medical condition which renders the participant physically incapable of performing strength exercises * serum total testosterone level at least 300ng/ml, unless patient and primary physician prepared to begin testosterone injections concurrent with study enrollment (men only).

Keywords: oxandrolone aids wasting strength training progressive resistance training exercise dietary intervention
a study evaluating the effects of glpg3970 given as oral treatment for 12 weeks in adults with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: this is a first exploration of glpg3970 in subjects with active systemic lupus erythematosus (sle) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (pk) profile, safety and tolerability, and pharmacodynamics (pd) biomarkers related to the investigational product (ip) mechanism of action and the pathophysiology of sle.


Eligibility criteria:
inclusion criteria: * sle diagnosis defined by american college of rheumatology (acr) 1997 criteria ≥4 * active arthritis in \>=4 active joints (according to 28 joint count) and/or cutaneous lupus erythematosus disease area and severity index (clasi) score \>=6. * anti-dsdna antibodies \>15 iu/ml. * stable standard-of-care (soc) therapy (defined as no change in prescription for at least 2 weeks prior to first ip dosing) consisting of the following permitted soc medications: * corticosteroids \<=20 mg/day (prednisone or equivalent) for at least 2 weeks prior to first ip dosing; and/or * non-steroidal anti-inflammatory drug (nsaids); and/or * one single antimalarial at a stable dose (hydroxychloroquine \<=5 mg/ kg/day, quinacrine 100 mg/day, or chloroquine 2.3 mg/kg/day) for at least 8 weeks prior to first ip dosing; and/or * one single immunosuppressant at a stable dose (azathioprine (aza) \<=2 mg/kg/day, methotrexate (mtx) \<=20 mg/week, or mycophenolate mofetil (mmf) \<=2 g/day) for at least 8 weeks prior to first ip dosing. * estimated glomerular filtration rate (egfr) \>=60 ml/min (according to chronic kidney disease epidemiology collaboration (ckd-epi)) this list only contains the key inclusion criteria. exclusion criteria: * lupus nephritis \>= class iii * severe organ manifestation or life-threatening lupus disease (active severe central nervous system lupus, severe pleuro-pericarditis, severe vasculitis). * severe acute respiratory syndrome coronavirus disease 2 (sars-cov-2) infection \>0 * unstable condition not related to sle * systemic inflammatory condition other than sle such as, but not limited to rheumatoid arthritis (ra), spondyloarthropathy, crohn's disease, ulcerative colitis, or psoriatic arthritis * sjögren's syndrome and/or antiphospholipid antibody syndrome who do not require treatment with any prohibited medication are not excluded. * active systemic infection * poorly controlled chronic cardiac, pulmonary, or renal disease. * known or suspected history of or a current immunosuppressive condition, or a history of invasive opportunistic infections * treatment with disallowed therapies this list only contains the key exclusion criteria.
app reminder on asa adherence

Conditions: Thromboembolic Event

Summary: the purpose of this study is to explore the impact of using a smartphone app reminder on medication adherence twice daily in adults prescribed 81 milligrams of aspirin for 35 days as anti-thrombotic therapy after knee or hip arthroplasty. this study will randomly assign participants to get usual postoperative care which is teaching with verbal instructions and printed information about taking the aspirin at the time of discharge, or to have an app on your smartphone with preset reminders in addition to usual postoperative discharge teaching after surgery.

the purpose of this study is to evaluate the impact of using a smartphone application (app) reminder on medication adherence twice daily in 200 adults prescribed 81 milligrams of aspirin (asa) for 35 days as anti-thrombotic therapy after knee or hip arthroplasty. the aim is to determine if an app downloaded on a smartphone that reminds patients twice a day to take their asa as prescribed will improve asa adherence and clinical outcomes for patients after total knee and total hip joint arthroplasty compared to those in the usual care. this is a two group, randomized control study with random assignment into the control group for usual care or the intervention group to receive a medication reminder app for their smart phone (daily for 35 days) plus usual care. participants will receive a baseline interview for demographic and other data and 36 day follow-up assessment, both conducted in person.

Eligibility criteria:
inclusion criteria: * prescribed aspirin 81 mg twice a day for 35 days * ability to write and speak english * have a smart phone with the capacity to download and set an app * own and use a smart phone for communication purposes exclusion criteria: * diagnosis of mental illness * do not own a smart phone

Keywords: orthopedics
melphalan, lenalidomide, and dexamethasone in treating patients with primary systemic amyloidosis

Conditions: Multiple Myeloma

Summary: rationale: drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing. biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop the abnormal plasma cells from growing. giving melphalan together with lenalidomide and dexamethasone may be an effective treatment for primary systemic amyloidosis. purpose: this phase ii trial is studying the side effects and how well giving melphalan together with lenalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.

objectives: primary * to determine the tolerability and safety of melphalan, lenalidomide, and dexamethasone, in terms of toxicity, in patients with primary systemic amyloidosis. * to determine the hematologic response rate in patients treated with this regimen. secondary * to assess organ response in patients treated with this regimen. outline: patients receive oral lenalidomide once daily on days 1-21, oral melphalan once daily on days 1-4, and oral dexamethasone once on days 1, 8, 15, and 22. treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. after completion of study therapy, patients are followed every 3 months until disease progression and then annually thereafter.

Eligibility criteria:
inclusion criteria: disease characteristics: * diagnosis of primary systemic amyloidosis patient characteristics: * not pregnant * negative pregnancy test * able to tolerate an anticoagulation regimen (e.g., 325 mg of aspirin per day, therapeutic warfarin, or low molecular weight heparin) prior concurrent therapy: * recovered from prior therapy * permanent or stable side effects/changes allowed * prior chemotherapy, thalidomide, lenalidomide, or steroids for amyloidosis allowed * more than 4 weeks since prior and no other concurrent cytotoxic chemotherapy or radiotherapy exclusion criteria: * no secondary or familial amyloidosis * no multiple myeloma (≥ 30% plasma cells in bone marrow biopsy or lytic bone lesions) * no prior cumulative doses of oral melphalan \> 200 mg * no more than one prior course of high-dose melphalan with stem cell transplant

Keywords: primary systemic amyloidosis
programme of acromegaly screening in patients with associated somatic disorders

Conditions: Acromegaly

Summary: the primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the help of laboratory (insulin-like growth factor i, growth hormone, oral glucose-tolerance test \[igf-1, gh, ogtt\]) and instrumental examination methods (magnetic resonance imaging \[mri\]).


Eligibility criteria:
inclusion criteria: * men and women aged 18 years and above with associated somatic disorders observed at the moscow endocrinology dispensary or endocrinology hospital at first moscow state medical university * patients who signed the informed consent form for participation in the survey before collection of any information. exclusion criteria: * patient already diagnosed with acromegaly * patient's refusal to participate in the survey.
venetoclax+azacytidine+modified bucy conditioning regimen for acute lymphoblastic leukemia undergoing allo-hsct

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia

Summary: the purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of ven-aza (venetoclax and azacytidine) followed by modified bucy (busulfan and cyclophosphamide) as conditioning regimen for high-risk or relapsed/refractory acute lymphoblastic leukemia (all) undergoing allogeneic hematopoietic stem cell transplantation (allo-hsct).

allogeneic hematopoietic stem cell transplantation (allo-hsct) is the only potentially curative therapy for patients with acute lymphoblastic leukemia. however, relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (hct) in patients, optimization of conditioning regimen can improve prognosis and decrease relapse. abnormal gene methylation is common in all patients. azacytidine is a dna methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells. venetoclax is a selective bcl-2 inhibitor, which has antitumor activity against a variety of hematological malignancies. the combination of the two drugs show a synergistic anti-tumor effect. multiple case reports the efficacy of venetoclax-based regimens in patients with all is encouraging. the objective of this study is to evaluate the feasibility, safety and efficacy of ven-aza bridging allogeneic hematopoietic stem cell transplantation in the treatment of high-risk all.

Eligibility criteria:
inclusion criteria: 1. age 14 to 65 years; 2. diagnosis of high-risk or relapsed/refractory acute lymphoblastic leukemia at the time of transplant. 3. must need a bone marrow transplant; 4. must have the ability to observe the efficacy and events; 5. patient must have ability to understand and willingness to provide written informed consent prior to participation in the study and any related procedures being performed. exclusion criteria: 1. age \ 65 years; 2. uncontrolled bacterial, viral, fungal, or other infection before conditioning regimen; 3. pregnant or lactating females; 4. current participation in another clinical trial; 5. contra-indication to one of the drug of the regimen; 6. any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo the agents included in the conditioning regimen

Keywords: venetoclax azacytidine hematopoietic stem cell transplantation acute lymphoblastic leukemia
ultrasound-guided transversalis fascia plane block versus caudal block for postoperative analgesia in children undergoing inguinal herniorrhaphy

Conditions: Ultrasound; Transversalis Fascia Plane Block; Caudal Block; Postoperative Analgesia; Children; Inguinal Herniorrhaphy

Summary: the aim of this study is to compare ultrasound-guided transversalis fascia plane block and caudal block for postoperative analgesia in children undergoing inguinal herniorrhaphy.

surgical repair of inguinal hernia is one of the most common day-case surgeries in the pediatric population. it is associated with significant postoperative pain and discomfort. caudal block analgesia is a popular and reliable technique for lower abdominal surgeries and found to be safe and effective for providing intra and postoperative analgesia in pediatric patients. transversal fascia plane block (tfpb) aims to provide analgesia for invasive procedures of the inguinal and sublingual areas by blocking the subcostal (t12), ilioinguinal (l1) and iliohypogastric (t12-l1) nerves. several studies have reported tfpb as the analgesic method of choice for procedures involving the t12-l1 dermatome region, including iliac bone graft harvesting, cesarean section, and inguinal hernia repair

Eligibility criteria:
inclusion criteria: * age from 1 to 7 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * scheduled for inguinal herniorrhaphy under general anesthesia (ga). exclusion criteria: * repeated surgeries. * known allergic reactions to any of the study's drugs. * infection at the site of block needle entry. * bleeding diathesis. * neurological disorders.
the effect of barefoot walking plantar chronic heel pain

Conditions: Plantar Fascitis

Summary: many patients suffer from chronic heel pain, and studies have not yet found the most appropriate treatment. there are some researchers who claim that the pain is caused by weakness in the muscles of the foot, which causes increased pressure in the heel. in walking, the muscles of the foot are activated and strengthened. no research has yet been done on whether walking (barefoot or with shoes) on a treadmill reduces pain in the heel and improves function.

a bare foot functions differently than a foot in a shoe while walking, as there are differences in movement, muscle tone, pressure and sensation. wearing shoes over the years can cause changes in walking and pain. in the examination of the feet of patients suffering from chronic pain in the heel was found a smaller volume of muscle, and calcification in the heel area that could be caused by increased pressure. although the trend of physiotherapy treatments has changed in recent years from passive to active treatments, the overwhelming majority of studies are testing passive therapies only as a treatment option for chronic heel pain. barefoot walking has not been tested as an option for treating chronic pain in the heel, although there are studies indicating that bare feet lead to reduced heel pressure, increased muscle work, and better proprioception.the purpose of this study is to examine the effect of barefoot walking on the level of pain, function and pain threshold for stress in patients with chronic heel pain.

Eligibility criteria:
inclusion criteria: * local pain in the heel that lasts more than 12 weeks, * pain in the first steps in the morning * pain that disappears in situations of weightlessness * ability to walk on a moving track. exclusion criteria: * pain in proximal areas along the leg or lower back pain that can radiate to the heel * sensory disorders for various reasons * tumors, fractures, previous operations in the lower extremities * irritable cardiovascular problems * balance problems and dizziness.

Keywords: chronic plantar heel pain barefoot treadmill plantar fascitis
study to investigate the safety and tolerability of azd8848 in butyrylcholinesterase deficient subjects

Conditions: Butyrylcholinesterase Deficiency

Summary: the purpose of this study is to investigate the safety and tolerability of azd8848 in butyrylcholinesterase deficient subjects in comparison with sex and age matched control subjects.

an open, non-controlled, non-randomised, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of azd 8848 administered intranasally to male and female butyrylcholinesterase deficient subjects and to sex and age matched controls

Eligibility criteria:
inclusion criteria: * bche deficient subjects: the half-live of azd8848 in plasma should be more than 20 minutes in an in vitro screening test * matched control subject: the half-live of azd8848 in plasma should be less than 2 minutes in an in vitro screening test exclusion criteria: * any clinically relevant abnormal findings in physical examination, laboratory assessments, vital signs or ecg * present or medical history of cardiovascular disease which, in the opinion of the investigator, may either put subject at risk because of participation in the study or influence the result of the study or the subject's ability to participate in the study * family history of autoimmune disease

Keywords: butyrylcholinesterase deficiency tolerability safety azd8848 pharmacokinetics pharmacodynamics bche deficient subjects and matched control subject
clinical trial of teriparatide in japan

Conditions: Osteoporosis

Summary: the purpose of this study is to assess the efficacy and safety of teriparatide in japanese postmenopausal women with osteoporosis.


Eligibility criteria:
inclusion criteria: * japanese women with primary osteoporosis * postmenopausal women aged at least 55 years * patients with a high risk for fracture exclusion criteria: * history of metabolic bone disorders other than osteoporosis * history of any secondary causes of osteoporosis * history of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated * severe or chronically disabling conditions other than osteoporosis
effects of training intensity on physical fitness and body composition in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: aim of the randomized controlled trial is to investigate the effects of endurance training with different intensities on physical performance, body composition and appetite regulation in people with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cystic fibrosis by at least 2 sweat tests and / or by the presence of two cf mutations, * willingness to participate in and to comply with the research project procedure, * written informed consent of patients, * age ≥ 18 years, * fev1 of pred. ≥ 40%, * stable condition (as indicated by absence of one or more signs: new or increased haemoptysis, increased malaise, fatigue or lethargy, temperature over 38°c, weight loss, sinus pain and a decrease in pulmonary function by 10% or more) exclusion criteria: * severe pulmonary exacerbation, * cor pulmonale, * musculoskeletal discomfort that makes a regular exercise training impossible, * untreated cf-related diabetes

Keywords: exercise training high intensity interval training (hiit) moderate intensity continuous training (mict) exercise capacity peak oxygen uptake (vo2peak) body-composition subjective appetite and satiety ratings appetite regulating hormones health related quality of life habitual physical activity ad libitum energy intake
low concentration atropine for myopia progression in school children

Conditions: Myopia Progression

Summary: myopia is the leading cause of blindness in taiwan. the younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. we have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. the aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (d) and astigmatism of -1.50 d or less.


Eligibility criteria:
inclusion criteria: myopia of at least -0.5 diopters (d) and astigmatism of -1.50 d or less. exclusion criteria: strabismus, amblyopia. cataract, glaucoma or any ocular diseases ocular surgery history systemic diseases (ex. asthma, heart disease...)

Keywords: myopia progression low concentration atropine